Evaluation of the Clinical Effects of Ombitasvir/Paritaprevir/ Ritonavir Regimen in the Treatment of Chronic HCV Patients in CKD Versus ESRD Patients in Assiut University Hospital

ESSAM M. ABD EL-AZIZ, M.D., SHALA Kh. EL-SHERIF, M.D.;; EL-LATIF ALI, M.Sc., MONA ABD

doi:10.21608/mjcu.2019.52539

Evaluation of the Clinical Effects of Ombitasvir/Paritaprevir/ Ritonavir Regimen in the Treatment of Chronic HCV Patients in CKD Versus ESRD Patients in Assiut University Hospital

Document Type : Original Article

Authors

The Departments of Internal Medecine & Endocrinology and Npherology, Faculty of Medicine, Assiut University, Egypt

10.21608/mjcu.2019.52539

Abstract

Abstract
Background: Assesing curability of Ombitasvir/Parit-aprevir/Ritonavir regimen in chronic HCV infected patients in those with ESRD and CKD.
Aim of Work: To asses, curability of Ombitasvir/Paritap-revir/Ritonavir in chronic HCV infected patients in those with ESRD vs CKD, and assess duration of sustained viral therapy in Assiut Hospital University.
Patients and Methods: It is a prospective study which included 40 patients at Hemodialysis unit and Internal Medicine department in Assiut University Hospitals though one year. Then Patient will be divided into 2 group: Group I: 20 ESRD Patients on regular heamodialysis >6 months with chronic HCV infection. Group II: 20 CKD Patients with chronic HCV infection did not start dialysis.
Results: (SVR) was assessed at 12 and 24 weeks post-therapy. All patients in each group achieved SVR at 12 weeks but at 24 week. 85% of patients with ESRD achieved SVR while all those with CKD achieved SVR.
Conclusion: We found that the curability of Ombitasvir /Paritaprevir/Ritonavir plus Ribavirin has SVR12 about 100% and SVR24 100% in CKD patients, 85% in ESRD patients. With less incidence of anemia with that regimen as only 10% patients need blood transfusion. With high tolerability and less side effects with no occurrence of discontinuation of treatment.

Keywords